Myocardial Infarction, Restenosis
Conditions
Brief summary
Evidence supporting use of bioabsorbable polymer drug eluting stents (BP-DES) is uncertain. Thus the investigators planned a meta-analysis to compare outcomes of BP-DES versus PP-DES in obstructive coronary artery disease.
Detailed description
Evidence supporting use of bioabsorbable polymer drug eluting stents (BP-DES) is uncertain. Previous studies suggested that BP-DES are at least as effective as durable polymer drug eluting stents (PP-DES). Thus the investigators planned a meta-analysis to compare outcomes of BP-DES versus PP-DES in obstructive coronary artery disease. Medline and Web databases were searched for studies comparing BP-DES and PP-DES for obstructive coronary disease, reporting rates of overall mortality, target lesion revascularization (TLR), myocardial infarction (MI), binary restenosis and late lumen loss (LLL) with a follow-up ≥ 6 months. Odds ratios (ORs) will be computed from individual studies and pooled according to a fixed effect (e.g. inverse variance weighting) or random effect model in case of statistical heterogeneity. Given the a priori heterogeneous nature of the observational analyses, separate subgroup analysis of studies with PLA bioabsorbable polymer loaded with biolimus A19 (BP-BES) is prespecified.
Interventions
PROCEDUREpercutaneous coronary intervention with stent
patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
Sponsors
Azienda Ospedaliero Universitaria Maggiore della Carita
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* randomized studies * studies reporting clinical outcomes as overall death and/or acute myocardial infarction and/or late stent thrombosis (ARC definition)\[\*\*\] and/or target lesion revascularization and/or late lumen loss * follow up period longer than 6 months.
Exclusion criteria
* duplicate reporting (in which case the manuscript reporting the largest sample or the longest follow-up was selected) * inability to compute risk estimates due to absence of clinical event in one of the groups * studies presenting composite major adverse cardiac event (MACE) and not individual end points.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| late coronary lumen loss | 9 month |
| target lesion revascularization | 9 month |
| overall mortality | 1 year |
| Late stent thrombosis | 1 year |
| Myocardial Infarction | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Binary restenosis | 9 months |
Countries
Italy
Outcome results
None listed